Welcome to our dedicated page for SCYNEXIS SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SCYNEXIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SCYNEXIS's regulatory disclosures and financial reporting.
SCYNEXIS, Inc. entered into a private placement with institutional and accredited investors to raise approximately $40.0 million in gross proceeds. The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants, and accompanying common warrants to purchase up to 43,500,000 shares or pre-funded warrants.
Common shares plus warrants are priced at $0.92 per unit, and pre-funded warrant units at $0.9199. Common warrants carry a $1.20 exercise price and become exercisable after stockholder approval of an authorized share increase. If all warrants are exercised for cash, SCYNEXIS could receive up to an additional $52.2 million.
The company plans to use net proceeds for working capital and general corporate purposes. It estimates that existing cash, cash equivalents and marketable securities, together with anticipated net proceeds from this financing, will fund operations into mid‑2029, supporting development of programs including SCY‑770 for autosomal dominant polycystic kidney disease.
SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire Poxel’s direct AMP kinase activator research program, including lead compound PXL-770, now SCY-770, for rare kidney disease ADPKD. SCYNEXIS will make a one-time upfront payment of $8,000,000 within 30 days of the agreement’s effective date and may pay up to $188,000,000 in development and commercial milestone payments tied to clinical progress and annual net sales thresholds.
The deal also includes an exclusive, sublicensable, perpetual worldwide license to related Poxel intellectual property. SCY-770 has been tested in eight clinical trials with a favorable safety profile and is planned to enter a Phase 2 proof-of-concept study in ADPKD in Q4 2026, with an early efficacy readout anticipated in the second half of 2027. SCY-770 holds FDA Orphan Drug Designation, while SCYNEXIS continues to develop its antifungal franchise, including potential BREXAFEMME milestones up to $146 million and ongoing Phase 1 work on SCY-247.
SCYNEXIS, Inc. focuses on severe fungal infections, built around its novel "fungerp" antifungal platform. Its first drug, ibrexafungerp (BREXAFEMME), is licensed globally to GSK for vulvovaginal candidiasis and recurrent VVC.
The lead wholly owned asset, SCY-247, completed single and multiple ascending dose Phase 1 oral studies in 88 healthy subjects, showing good tolerability and generally dose‑proportional pharmacokinetics. An intravenous Phase 1 trial began in early 2026, with a Phase 2 invasive candidiasis study planned for 2026.
Under a GSK license, SCYNEXIS ran the MARIO Phase 3 ibrexafungerp study, then agreed in an October 2025 memorandum to wind it down, receiving one‑time payments totaling $24.8 million in addition to a $10.0 million development milestone earlier in 2025.
SCYNEXIS reported an accumulated deficit of about $385.1 million and cash, cash equivalents and investments of $56.3 million as of December 31, 2025. The company expects continuing operating losses and will require substantial additional capital while it advances SCY‑247 and evaluates further partnering and in‑licensing opportunities.
Avidity Partners and affiliates reported a significant passive stake in Scynexis, Inc. common stock on Schedule 13G/A (Amendment No. 8). The group, including Avidity Partners Management LP and Michael Gregory, is shown as beneficially owning 4,426,565 shares, representing 9.9% of Scynexis’s common stock as of the event date.
The holdings are largely split between Avidity Master Fund LP with 852,750 shares (2.0% of the class) and Avidity Private Master Fund I LP with 3,573,815 shares (8.1% of the class), over which the reporting persons share voting and dispositive power. They certify the securities were not acquired to change or influence control of Scynexis.
SCYNEXIS, Inc. received an amended Schedule 13G/A from Kingdon Capital Management, L.L.C. and Mark Kingdon reporting that they now beneficially own 0 shares of the company’s common stock, or 0% of the class, as of December 31, 2025.
They report no sole or shared voting or dispositive power over any SCYNEXIS shares and indicate ownership of 5 percent or less of the class. They also certify that any securities previously held were not acquired to change or influence control of the company.
SCYNEXIS Inc. reported an equity award to its Chief Financial Officer. On 01/29/2026, CFO Macleod Ivor received 129,833 shares of common stock at a price of $0, reported as an acquisition.
These shares represent restricted stock units that vest in three equal annual installments starting February 28, 2026. Following this grant, the officer beneficially owns 398,529 shares directly.
SCYNEXIS Inc. granted equity compensation to its Chief Legal Officer, Scott Sukenick. On January 29, 2026, he received 129,833 shares of common stock at a price of $0 per share in the form of restricted stock units. These units vest one third per year over three years starting February 28, 2026, providing time-based retention incentives. Following this grant, he beneficially owns 574,539 shares of SCYNEXIS common stock in direct ownership.
SCYNEXIS Inc. reported an equity award to its CEO, David Angulo Gonzalez. On January 29, 2026, he received 391,333 shares of common stock as a stock-based grant priced at $0 per share, structured as restricted stock units.
After this award, he beneficially owned 1,244,431 shares of SCYNEXIS common stock in total. The restricted stock units vest in three equal annual installments, with vesting measured from February 28, 2026, which ties the award to multi‑year service and performance with the company.
Federated Hermes, Inc. and related reporting persons filed an amended Schedule 13G/A reporting beneficial ownership of 3,533,250 shares of SCYNEXIS, INC. common stock, representing 8.42% of the class as of 12/31/2025. Federated Hermes has sole voting and dispositive power over these shares, while the Voting Shares Irrevocable Trust reports the same sole voting and dispositive power.
Individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue each report shared voting and shared dispositive power over the same 3,533,250 shares and the same 8.42% stake. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of SCYNEXIS. They also expressly disclaim beneficial ownership of securities held by the managed funds.
SCYNEXIS (SCYX) reported Q3 2025 results. License revenue was $334,000, down from $660,000 a year ago. Operating expenses fell to $8.7 million, led by lower R&D at $5.5 million and SG&A of $3.3 million. The company posted a net loss of $8.6 million, or $0.17 per share, including a $0.6 million loss from warrant fair value adjustments.
Cash, cash equivalents, and short-term investments totaled $37.9 million as of September 30, 2025. Convertible notes were repaid at maturity in March 2025, reducing current debt to zero. A $10.0 million license receivable is on the balance sheet tied to the GSK collaboration.
After quarter-end, SCYNEXIS and GSK signed a binding memorandum of understanding under which SCYNEXIS will wind down the MARIO study and receive one-time payments totaling $24.8 million. Other potential milestones and royalties under the GSK license remain unchanged. The company also disclosed a Nasdaq minimum bid price notice received on June 20, 2025, with a compliance period through December 17, 2025.